What is LITS's earnings growth forecast for 2027-2027?
(NASDAQ: LITS) Lite Strategy's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 100.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,331.32%.
Lite Strategy's earnings in 2026 is -$60,820,000.
In 2027, LITS is forecast to generate -$54,140,898 in earnings, with the lowest earnings forecast at -$52,017,726 and the highest earnings forecast at -$55,733,278.
What is LITS's revenue growth forecast for 2027-2027?
(NASDAQ: LITS) Lite Strategy's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 21.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.2%.
Lite Strategy's revenue in 2026 is $0.
In 2027, LITS is forecast to generate $867,642,600 in revenue, with the lowest revenue forecast at $833,617,400 and the highest revenue forecast at $893,161,500.
What is LITS's forecast return on assets (ROA) for 2027-2027?
(NASDAQ: LITS) forecast ROA is -93.69%, which is lower than the forecast US Biotechnology industry average of -25.24%.
What is LITS's Earnings Per Share (EPS) forecast for 2027-2027?
(NASDAQ: LITS) Lite Strategy's current Earnings Per Share (EPS) is -$2.00. In 2027, LITS's EPS is forecast to hit -$1.59 (min: -$1.53, max: -$1.64).
What is LITS's forecast return on equity (ROE) for 2027-2027?
(NASDAQ: LITS) forecast ROE is -95.26%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.